ORGN 383 |
Advances in the asymmetric synthesis of the quinone methide natural product Kendomycin
| Khalida Shamim and David R. Williams. Department of Chemistry, Indiana University, 800 E. Kirkwood Avenue, Bloomington, IN 47401 |
| Kendomycin is an 18-membered ansa-bridged antibiotic which has recently been isolated from the mycelium of Streptomyces violaceoruber. Kendomycin has been described as a potent endothelin receptor antagonist and antiosteoporotic agent. Remarkable antibacterial activity against Gram-positive and Gram-negative organisms, especially multiresistant Staphylococcus aureus (MRSA) stains has also been reported. Cytotoxicity studies for kendomycin against stomach adenocarcinoma (HM02), heptacellular carcinoma (HEPG2), and breast adenocarcinoma (MCF7) cell lines demonstrate comparable potency to doxorubicin and greater activity (GI50 growth inhibition) than cisplatin. Recently we initiated efforts to develop a stereocontrolled synthesis of the natural product. A summary of these efforts will be presented. 
|
| |
|
Total Synthesis, Process R&D, Combinatorial, Bioorganic, Physical Organic Chemistry
8:00 PM-10:00 PM, Tuesday, August 24, 2004 Pennsylvania Convention Center -- Hall D, Poster
Sci-Mix
8:00 PM-10:00 PM, Monday, August 23, 2004 Pennsylvania Convention Center -- Hall D, Sci-Mix
Division of Organic Chemistry
The 228th ACS National Meeting, in Philadelphia, PA, August 22-26, 2004
|